Cases and Conversations™ in Multiple Myeloma: Nursing Considerations for Managing Relapsed/Refractory Disease

Release Date: May 25, 2021
Expiration Date: May 25, 2022

Activity Overview

Though multiple myeloma (MM) remains incurable, the last 15 years have yielded improved clinical outcomes, with response rates rising as high as 30% with monotherapy and up to 90% with combination therapies. With new treatments that offer the potential to improve progression-free survival (PFS) and overall survival (OS) for patients with MM in the relapsed/refractory setting, multidisciplinary care is a crucial element of support for patients. Oncology nurses occupy a unique position on the multidisciplinary care team; through frequent interaction with patients and caregivers, they ensure that patients benefit from new clinical advances by providing supportive measures conducive to adherence and uninterrupted treatment.

The goal of this educational activity is to provide oncology nurses with the knowledge and competence to appropriately and safely incorporate new agents and regimens for relapsed/refractory MM, thereby optimizing the management of patients throughout their disease course.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Sanofi Genzyme.

Target Audience

This educational activity is directed toward nurses and other health care professionals involved in the treatment of patients with MM.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Understand the impact of disease-specific factors, treatment history, and risk stratification on therapy decisions using novel agents or combinations in MM.
• Assess the efficacy and safety profile for novel agents and combinations in multiple lines of care among patients with MM.
• Determine treatment-related toxicities associated with the wide diversity of new therapeutic strategies for MM to maximize clinical outcomes.
• Apply knowledge of evidence-based toxicity profiles of novel agents for MM to facilitate effective counseling, patient education, and empowerment

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Charise Gleason, MSN, NP-BC, AOCNP
Advance Practice Provider Chief
Department of Hematology and Medical Oncology
Adjunct Faculty, Nell Hodgson Woodruff School of Nursing
Winship Cancer Institute of Emory University
Atlanta, GA

Disclosures: no relevant financial relationships with ineligible companies.

Kathryn Maples, PharmD, BCOP
Clinical Pharmacy Specialist, Multiple Myeloma
Winship Cancer Institute of Emory University
Atlanta, GA

Disclosures: Consultant: GlaxoSmithKline, Karyopharm Therapeutics, Sanofi.

Kimberly Noonan, DNP, ANP-BC, AOCN
Nurse Practitioner
Dana-Farber Cancer Institute
Boston, MA

Disclosures: no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.